Список литературы

Поставить закладку

Kitchens C.S. Disseminated Intravascular Coagulation. In: Kitchens C.S., ed. Consultative Hemostasis and Thrombosis. W.B.: Saunders Company; 2007. 165-178.
Ralph AG, Brainard BM; Update on disseminated intravascular coagulation: when to consider it, when to expect it, when to treat it. Top Companion Anim Med. 2012 May 27(2):65-72.
Asakura H. Classifying types of disseminated intravascular coagulation: clinical and animal models. J Intensive Care. 2014;2:20.
Thachil J et al. Management of cancer -associated disseminated intravascular coagulation: guidance from the SSC of the ISTH. J Thromb Haemost. 2015.
Kaneko T, Wada H; Diagnostic criteria and laboratory tests for disseminated intravascular coagulation. J Clin Exp Hematop. 2011 51(2):67-76.
Воробьева Н.А., Капустин С.И. Роль генетических полиморфизмов системы гемостаза в формировании полиорганной недостаточности при остром ДВС-синдроме. Анестезиология и реаниматология. 2007; №2: 52-55.
Taylor F.B., Ton C.H., Hoots W. K. et al. Scientific and Standardization Committee Communications: Towards a Definition. Clinical and Laboratory Criteria, and a Scoring System for Disseminated Intravasciilar Coagulation. Scientific Subcommittee on Disseminated Intravascular Coagulation (DIG) of the International Society on Thrombosis and Haemostasis; 2001.
Blasi A. Coagulopathy in liver disease: Lack of an assessment tool. World J Gastroenterol 2015; 21(35): 10062-10071.
Boccardo P, Remuzzi G, Galbusera M. Platelet dysfunction in renal failure. Semin Thromb Hemost 2004; 30:579–589.
Rossaint R, Bouillon B, Cerny V et al. The European guideline on management of major bleeding and coagulopathy following trauma: fourth edition. Critical Care 2016; 20:100.
Deloughery T.G. Hemorrhagic and Thrombotic Disorders in the Intensive Care Setting. In: Kitchens C.S., ed. Consultative Hemostasis and Thrombosis. W.B.: Saunders Company; 2007. 493-514.
Marcucci C.E., Schoettker P. Perioperative Hemostаsis. Springer; 2015. 454 s.
Antiphospholipid Syndrome: Insights and Highlights from the 13th International Congress on Antiphospholipid Antibodies D. Erkan and S.S. Pierangeli (eds.), DOI 10.1007/978-1-4614-3194-7_17, © Springer Science+Business Media New York 2012
Miyakis S, Lockshin M, Atsumi T, et al. International consensus statement on an update of the classifi cation criteria for defi nite antiphospholipid syndrome (APS). J Thromb Haemost. 2006,4,295–306
Asherson RA, Cervera R, de Groot PR, et al. Catastrophic antiphospholipid syndrome: inter- national consensus statement on classification criteria and treatment guidelines. Lupus. 2003,12,530–534
Kitchens C.S. Surgery and hemostasis. In: Kitchens C.S., ed. Consultative Hemostasis and Thrombosis. W.B.: Saunders Company; 2007. 463-480.
Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Guidelines for the management of hemophilia. Haemophilia 2013; 19:e1–e47.
Blanchette VS, Key NS, Ljung LR, et al. Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost 2014; 12:1935–1939.
Laffan MA, Lester W, O’Donnell JS, et al. The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology. Br J Haematol 2014; 167:453–465.
Narr BJ, Warner ME, Schroeder DR, Warner MA. Outcomes of patients with no laboratory assessment before anesthesia and a surgical procedure. Mayo Clin Proc. 1997 Jun;72(6):505-9.
Suchman AL, Mushlin AI. How well does the activated partial thromboplastin time predict postoperative hemorrhage? JAMA. 1986 Aug 8;256(6):750-3.
СпиридоноваЕ.А., ЩукинВ.В., ЖарковП.А., АтауллахановФ.И., ЗейналовА.М., БаландинаА.Н., КарелинА.Ф., ШимширтМ.А., СманцерВ.А., СеливановВ.В., ОвсянниковЮ.Г. Периоперационный гемостазиологический мониторинг: цель и лабораторное сопровождение. Вестник интенсивной терапии 2016; 1:37-46
Заболотских И.Б., Синьков С.В., Лебединский К.М., Буланов А.Ю. Периоперационное ведение больных с нарушениями системы гемостаза // Вестник интенсивной терапии . - 2015. - № 1. - С. 65-77.
Weber CF, Gorlinger K, Meininger D, Herrmann E, Bingold T, Moritz A, et al. Point-of-care testing: a prospective, randomized clinical trial of efficacy in coagulopathic cardiac surgery patients. Anesthesiology. 2012;117(3):531–47.
Karkouti K, McCluskey SA, Callum J, Freedman J, Selby R, Timoumi T, et al. Evaluation of a novel transfusion algorithm employing point-of-care coagulation assays in cardiac surgery: a retrospective cohort study with interrupted time-series analysis. Anesthesiology. 2015;122(3):560–70.
Girdauskas E, Kempfert J, Kuntze T, et al. Thromboelastometrically guided transfusion protocol during aortic surgery with circulatory arrest: a prospective, randomized trial. JThoracCardiovascSurg 2010; 140:1117–1124; e1112.
Буланов А. Ю. Тромбоэластография в современной клинической практике: атлас ТЭГ. Москва : Ньюдиамед, 2015. - 114 с.
da Luz LT, Nascimento B, Rizoli S. Thrombelastography (TEG(R)): practical considerations on its clinical use in trauma resuscitation. Scand J Trauma Resusc Emerg Med. 2013;21:29.
Trzebicki J, Flakiewicz E, Kosieradzki M, et al. The use of thromboelastometry in the assessment of hemostasis during orthotopic liver transplantation reduces the demand for blood products. Ann Transplant 2010; 15:19–24.
Walker C, Ingram M, Edwards D, Wood P. Use of thromboelastometry in the assessment of coagulation before epidural insertion after massive transfusion. Anaesthesia 2011; 66:52–55.
Doran CM, Woolley T, Midwinter MJ. Feasibility of using rotational thromboelastometry to assess coagulation status of combat casualties in a deployed setting. J Trauma 2010; 69 (Suppl 1):S40–48.
Lee SH, Lee SM, Kim CS, et al. Use of fibrin-based thromboelastometry for cryoprecipitate transfusion in cardiac surgery involving deep hypothermic circulatory arrest during cardiopulmonary bypass. Blood Coagul Fibrinolysis 2010; 21:687–691.
Буланов А.Ю., Яцков К.В., Буланова Е.Л., Доброва Н.В. Тромбоэластография: клиническая значимость теста на функциональный фибриноген. Вестник интенсивной терапии 2017; 1:5-11
Wada H, Thachil J, Di Nisio M, Kurosawa S, Gando S, Toh CH. Harmonized guidance for disseminated intravascular coagulation from the International Society on Thrombosis and Haemostasis and the current status of anticoagulant therapy in Japan: a rebuttal.Scientific and Standardization Committee on DIC of the International Society on Thrombosis and Haemostasis.J Thromb Haemost. 2013 Nov;11(11):2078-9.
Тромбоз и гемостаз. Шкалы и алгоритмы (пособие под ред. Ройтмана Е.В. и Левшина Н.Ю.). М:2016. 62 с.
Stravitz T.R, Lisman T, Luketic VA, et al. Minimal effects of acute liver injury/acute liver failure on hemostasis as assessed by thromboelastography. J Hepatol 2011; 56: 129–36.
Agarwal B, Wright G, Gatt A, et al. Evaluation of coagulation abnormalities in Acute Liver Failure. J. Hepatol 2012; 57: 780–6.
Wada H, Asakura H, Okamoto K, Iba T, Uchiyama T, Kawasugi K, Koga S, Mayumi T, Koike K, Gando S, Kushimoto S, Seki Y, Madoiwa S, Maruyama I, Yoshioka A, Japanese Society of Thrombosis Hemostasis/DIC subcommittee. Expert consensus for the treatment of disseminated intravascular coagulation in Japan. Thromb Res 2010; 125: 6–11.
Wada H, Thachil J, Di Nisio, M, Mathew P, Kurosawa S, Gando S, Kim HK, Nielsen JD, Dempfle C-E, Levi M, Toh CH. Guidance for diagnosis and treatment of disseminated intravascular coagulation from harmonization of the recommendations from three guidelines. J Thromb Haemost 2013; 11: 761–7.
Kawasugi K, Wada H, Hatada T, Okamoto K, Uchiyama T, Kushimoto S, Seki Y, Okamura T, Nobori T, Japanese Society of Thrombosis Hemostasis/DIC subcommittee. Prospective evaluation of hemostatic abnormalities in overt DIC due to various underlying diseases. Thromb Res 2011; 128: 186–90.
Patel R, Cook DJ, Meade MO, Griffith LE, Mehta G, Rocker GM, Marshall JC, Hodder R, Martin CM, Heyland DK, Peters S, Muscedere J, Soth M, Campbell N, Guyatt GH: Burden of illness in venous thromboembolism in critical care: a multicenter observational study. J Crit Care 2005, 20:341–347.
Gando S, Wada H, Thachil J, Scientific and Standardization Committee on DIC of the International Society on Thrombosis and Haemostasis (ISTH): Differentiating disseminated intravascular coagulation (DIC) with the fibrinolytic phenotype from coagulopathy of trauma and acute coagulopathy of trauma-shock (COT/ACOTS). J Thromb Haemost 2013, 11:826– 835.
Pernerstorfer T, Hollenstein U, Hansen J, Knechtelsdorfer M, Stohlawetz P, Graninger W, Eichler HG, Speiser W, Jilma B. Heparin blunts endotoxin-induced coagulation activation. Circulation 1999; 100: 2485–90.
Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, Chalupa P, Atherstone A, Penzes I, Kubler A, Knaub S, Keinecke HO, Heinrichs H, Schindel F, Juers M, Bone RC, Opal SM. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001; 286: 1869–78.
Aoki N, Matsuda T, Saito H, Takatsuki K, Okajima K, Takahashi H, Takamatsu J, Asakura H, Ogawa N, CTC-111-IM Clinical Research Group. A comparative double-blind randomized trial of activated protein C and unfractionated heparin in the treatment of disseminated intravascular coagulation. Int J Hematol 2002; 75: 540–7.
Saito H, Maruyama I, Shimazaki S, Yamamoto Y, Aikawa N, Ohno R, Hirayama A, Matsuda T, Asakura H, Nakashima M, Aoki N. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost 2007; 5: 31–41.
Mannucci PM, Levi M. Prevention and treatment of major blood loss. N Engl J Med 2007; 356: 2301–11.
Youssef WI, Salazar F, Dasarathy S, Beddow T, Mullen KD. Role of fresh frozen plasma infusion in correction of coagulopathy of chronic liver disease: a dual phase study. Am J Gastroenterol. 2003;98(6):1391-1394.
Stravitz RT, Kramer AH, Davern T, et al. Intensive care of patients with acute liver failure: recommendations of the U.S. Acute Liver Failure Study Group. Crit Care Med 2007; 35:2498–2508.
Chowdary P, Saayman AG, Paulus U, Findlay GP, Collins PW. Efficacy of standard dose and 30 ml/kg fresh frozen plasma in correcting laboratory parameters of haemostasis in critically ill patients. Br J Haematol 2004; 125:69–73.
Giannini EG, Greco A, Marenco S, Andorno E, Valente U, Savarino V. Incidence of bleeding following invasive procedures in patients with thrombocytopenia and advanced liver disease. Clin Gastroenterol Hepatol 2010; 8:899–902.
Segal JB, Dzik WH. Paucity of studies to support that abnormal coagulation test results predict bleeding in the setting of invasive procedures: an evidence-based review. Transfusion 2005; 45: 1413-1425.
O’Shaughnessy DF, Atterbury C, Bolton Maggs P, Murphy M, Thomas D, Yates S, Williamson LM. Guidelines for the use of freshfrozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol 2004; 126: 11-28.
Lorenz R, Kienast J, Otto U, et al. Efficacy and safety of a prothrombin complex concentrate with two virus-inactivation steps in patients with severe liver damage. Eur J Gastroenterol Hepatol. 2003;15(1):15-20.
Segal JB, Dzik WH. Paucity of studies to support that abnormal coagulation test results predict bleeding in the setting of invasive procedures: an evidence-based review. Transfusion. 2005;45(9): 1413-1425.
O’Shaughnessy DF, Atterbury C, Bolton MP, et al. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol. 2004;126(1):11-28.
Porte RJ, Molenaar IQ, Begliomini B, et al. Aprotinin and transfusion requirements in orthotopic liver transplantation: a multicentre randomized double-blind study. EMSALT Study Group. Lancet. 2000;355(9212):1303-1309.
Boylan JF, Klinck JR, Sandler AN, et al. Tranexamic acid reduces blood loss, transfusion requirements, and coagulation factor use in primary orthotopic liver transplantation. Anesthesiology. 1996;85(5):1043-1048.
Hendriks HG, Meijer K, de Wolf JT, et al. Reduced transfusion requirements by recombinant factor VIIa in orthotopic liver transplantation: a pilot study. Transplantation. 2001;71(3):402405.
Lodge JP, Jonas S, Jones RM, et al. Efficacy and safety of repeated perioperative doses of recombinant factor VIIa in liver transplantation. Liver Transpl. 2005;11(8):973-979.
Planinsic R, van der Meer J, Testa G, et al. Safety and efficacy of a single bolus administration of recombinant factor VIIa in liver transplantation due to chronic liver disease. Liver Transpl. 2005; 11(8):895-900.
Hedges SJ, Dehoney SB, Hooper JS, Amanzadeh J, Busti AJ. Evidencebased treatment recommendations for uremic bleeding. Nat Clin Pract Nephrol 2007; 3:138–153.
Manno C, Bonifati C, Torres DD, Campobasso N, Schena FP. Desmopressin acetate in percutaneous ultrasound-guided kidney biopsy: a randomized controlled trial. Am J Kidney Dis 2011; 57:850–855.
Vigano G, Gaspari F, Locatelli M, Pusineri F, Bonati M, Remuzzi G. Doseeffect and pharmacokinetics of estrogens given to correct bleeding time in uremia. Kidney Int 1988; 34:853–858.
Holcomb JB, Jenkins D, Rhee P, Johannigman J, Mahoney P, Mehta S, et al. Damage control resuscitation: directly addressing the early coagulopathy of trauma. J Trauma. 2007;62(2):307–10.
Dente CJ, Shaz BH, Nicholas JM, Harris RS, Wyrzykowski AD, Patel S, et al. Improvements in early mortality and coagulopathy are sustained better in patients with blunt trauma after institution of a massive transfusion protocol in a civilian level I trauma center. J Trauma. 2009;66(6):1616–24.
Bulger EM, May S, Brasel KJ, Schreiber M, Kerby JD, Tisherman SA, et al. Out-of-hospital hypertonic resuscitation following severe traumatic brain injury: a randomized controlled trial. JAMA. 2010;304(13):1455–64.
Ketchum L, Hess JR, Hiippala S. Indications for early fresh frozen plasma, cryoprecipitate, and platelet transfusion in trauma. J Trauma. 2006;60(6 Suppl):S51–8.
Holcomb JB, Hess JR. Early massive trauma transfusion: state of the art: editor’s introduction. JTraumaAcuteCareSurg. 2006;60(6):S1–2.
Holcomb JB, Tilley BC, Baraniuk S, Fox EE, Wade CE, Podbielski JM, et al. Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial. JAMA. 2015;313(5):471–82.
Baraniuk S, Tilley BC, del Junco DJ, Fox EE, van Belle G, Wade CE, et al. Pragmatic Randomized Optimal Platelet and Plasma Ratios (PROPPR) Trial: design, rationale and implementation. Injury. 2014;45(9):1287–95.
Toy P, Popovsky MA, Abraham E, Ambruso DR, Holness LG, Kopko PM, et al. Transfusion-related acute lung injury: definition and review. Crit Care Med. 2005;33(4):721–6.
Holness L, Knippen MA, Simmons L, Lachenbruch PA. Fatalities caused by TRALI. Transfus Med Rev. 2004;18(3):184–8.
CRASH-2 Trial Collaborators, Shakur H, Roberts I, et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo controlled trial. Lancet. 2010; 376:23e32.
Roberts I, Shakur H, Afolabi A et al. The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. Lancet. 2011; 377(9771):1096–101.1101e1091–1092.
Roberts I, Shakur H, Ker K et al. Antifibrinolytic drugs for acute traumatic injury. Cochrane Database Syst Rev. 2012; 12:CD004896.
Roberts I, Prieto-Merino D, Manno D. Mechanism of action of tranexamic acid in bleeding trauma patients: an exploratory analysis of data from the CRASH-2 trial. Crit Care. 2014; 18(6):685.
Roberts I, Perel P, Prieto-Merino D et al. Effect of tranexamic acid on mortality in patients with traumatic bleeding: prespecified analysis of data from randomised controlled trial. BMJ. 2012; 345:e5839.
Kozek-Langenecker SA, Ahmed AB., Afshari A et al. Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology. Eur J Anaesthesiol 2017; 34:332–395
Афончиков В.С., Михеева А.В. Гиперфибринолизиретракциясгустка крови при шокогенной травме. Вестник интенсивной терапии 2016; 3:47-52
Gayet-Ageron A, Prieto-Merino D, Ker K et al. Effect of treatment delay on the effectiveness and safety of antifibrinolytics in acute severe haemorrhage: a meta-analysis of individual patient-level data from 40138 bleeding patients. Lancet.2018 Jan 13;391(10116): 125–132.
Schöchl H, Nienaber U, Hofer G et al. Goal-directed coagulation management of major trauma patients using thromboelastometry (ROTEMW)-guided administration of fibrinogen concentrate and prothrombin complex concentrate. Crit Care 2010, 14:R55.
Shaz BH, Dente CJ, Nicholas J et al. Increased number of coagulation products in relationship to red blood cell products transfused improves mortality in trauma patients. Transfusion. 2010; 50(2):493–500.
Hiippala ST, Myllyla GJ, Vahtera EM. Hemostatic factors and replacement of major blood loss with plasma-poor red cell concentrates. Anesth Analg. 1995;81(2):360–5.
Schöchl H, Cotton B, Inaba K, et al. FIBTEM provides early prediction of massive transfusion in trauma. Crit Care. 2011; 15(6):R265.
Stinger HK, Spinella PC, Perkins JG et al. The ratio of fibrinogen to red cells transfused affects survival in casualties receiving massive transfusions at an army combat support hospital. Journal of Trauma 2008; 64(2 Suppl):S79–85. 
Schöchl H, Nienaber U, Maegele M et al. Transfusion in trauma: thromboelastometry-guided coagulation factor concentrate-based therapy versus standard fresh frozen plasma-based therapy. Crit Care. 2011; 15(2):R83.
Nardi G, Agostini V, Rondinelli B et al. Traumainduced coagulopathy: impact of the early coagulation support protocol on blood product consumption, mortality and costs. Crit Care. 2015; 19(1):83.
Stansbury LG, Hess AS, Thompson K et al. The clinical significance of platelet counts in the first 24 hours after severe injury. Transfusion. 2013; 53(4):783–9.
Johansson PI, Stensballe J, Rosenberg I et al. Proactive administration of platelets and plasma for patients with a ruptured abdominal aortic aneurysm: evaluating a change in transfusion practice. Transfusion. 2007; 47(4):593–8.
Joseph B, Aziz H, Zangbar B et al. Acquired coagulopathy of traumatic brain injury defined by routine laboratory tests: which laboratory values matter? J Trauma Acute Care Surg. 2014; 76(1):121–5.
Kashuk JL, Moore EE, Johnson JL et al. Postinjury life threatening coagulopathy: is 1:1 fresh frozen plasma:packed red blood cells the answer? Journal of Trauma 2008; 65(2):261–270.
Nekludov M, Bellander BM, Blomback M, Wallen HN. Platelet dysfunction in patients with severe traumatic brain injury. J Neurotrauma. 2007; 24(11):1699–706.
Wohlauer MV, Moore EE, Thomas S et al. Early platelet dysfunction: an unrecognized role in the acute coagulopathy of trauma. J Am Coll Surg. 2012; 214(5):739–46.
Counts RB, Haisch C, Simon TL et al. Hemostasis in massively transfused trauma patients. Ann Surg. 1979; 190(1):91–9.
Ciavarella D, Reed RL, Counts RB et al. Clotting factor levels and the risk of diffuse microvascular bleeding in the massively transfused patient. Br J Haematol. 1987; 67(3):365–8.
Holcomb JB, Wade CE, Michalek JE et al. Increased plasma and platelet to red blood cell ratios improves outcome in 466 massively transfused civilian trauma patients. Ann Surg. 2008; 248(3):447–58.
Zink KA, Sambasivan CN, Holcomb JB et al. A high ratio of plasma and platelets to packed red blood cells in the first 6 hours of massive transfusion improves outcomes in a large multicenter study. Am J Surg. 2009; 197(5):565–70. discussion 570.
McQuilten ZK, Crighton G, Engelbrecht et al. Transfusion interventions in critical bleeding requiring massive transfusion: a systematic review. Transfus Med Rev. 2015; 29(2):127–37.
Ho KM, Leonard AD. Concentration-dependent effect of hypocalcaemia on mortality of patients with critical bleeding requiring massive transfusion: a cohort study. Anaesth Intensive Care. 2011; 39(1):46–54.
Lier H, Krep H, Schroeder S, Stuber F. Preconditions of hemostasis in trauma: a review. The influence of acidosis, hypocalcemia, anemia, and hypothermia on functional hemostasis in trauma. J Trauma. 2008; 65(4):951–60.
Perkins JG, Cap AP, Weiss BM et al. Massive transfusion and nonsurgical hemostatic agents. Crit Care Med. 2008; 36(7 Suppl):S325–39.
Quinlan DJ, Eikelboom JW, Weitz JI. Four-factor prothrombin complex concentrate for urgent reversal of vitamin K antagonists in patients with major bleeding. Circulation. 2013; 128(11):1179–81.
Sarode R, Milling Jr TJ, Refaai MA et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation. 2013; 128(11):1234–43.
Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebocontrolled, crossover study in healthy subjects. Circulation. 2011;124(14):1573–9.
Marlu R, Hodaj E, Paris A, Albaladejo P, Crackowski JL, Pernod G. Effect of nonspecific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost. 2012;108(2):217–24.
Clave A, Fazilleau F, Dumser D, Lacroix J. Efficacy of tranexamic acid on blood loss after primary cementless total hip replacement with rivaroxaban thromboprophylaxis: a casecontrol study in 70 patients. Orthop Traumatol Surg Res. 2012;98(5):484–90.
Goldstein JN, Refaai MA, Milling Jr TJ et al. Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial. Lancet. 2015; 385(9982):2077–87.
Huttner HB, Schellinger PD, Hartmann M et al. Hematoma growth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant therapy: comparison of acute treatment strategies using vitamin K, fresh frozen plasma, and prothrombin complex concentrates. Stroke. 2006; 37(6):1465–70.
Edavettal M, Rogers A, Rogers F et al. Prothrombin complex concentrate accelerates international normalized ratio reversal and diminishes the extension of intracranial hemorrhage in geriatric trauma patients. Am Surg. 2014; 80(4):372–6.
Baglin TP, Keeling DM, Watson HG. Guidelines on oral anticoagulation (warfarin): third edition–2005 update. Br J Haematol. 2006; 132(3):277–85.
Hauser CJ, Boffard K, Dutton R et al. Results of the CONTROL trial: efficacy and safety of recombinant activated Factor VII in the management of refractory traumatic hemorrhage. J Trauma. 2010; 69(3):489–500.
Knudson MM, Cohen MJ, Reidy R et al. Trauma, transfusions, and use of recombinant factor VIIa: a multicenter case registry report of 380 patients from the Western Trauma Association. J Am Coll Surg. 2011; 212(1):87–95.
Mitra B, Cameron PA, Parr MJ, Phillips L. Recombinant factor VIIa in trauma patients with the ‘triad of death’. Injury. 2012; 43(9):1409–14.
British Committee for Standards in Haematology. Guidelines for the use of platelet transfusions. BritishJournalofHaematology, 2017; 176: 365–394.
Клинические рекомендации по диагностике и лечению атипичного гемолитикоуремического синдрома. Научное общество нефрологов России, 2015.
FinazziG, MarchioliR, BrancaccioV, etal. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J .Thromb. Haemost. 2005,3,848– 853.
Urbanus RT, Siegerink B, Roest M, Rosendaal FR, De Groot PG, Algra A. Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case–control study. Lancet Neurol. 2009,8,998–1005.
Asherson RA, Cervera R, Piette JC, et al. Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients. Medicine (Baltimore). 2001,80,355–376.
Erkan D. Therapeutic and prognostic considerations in catastrophic antiphospholipid syn- drome. Autoimmun. Rev. 2006,6,98–103.
Решетняк Т.М. Лечение антифосфолипидного синдрома: современные стандарты. Тромбоз, гемостазиреология. 2016; №1: 11-20.
Hermans C, Altisent C, Batorova A, et al. Replacement therapy for invasive procedures in patients with haemophilia: literature review, European survey and recommendations. Haemophilia 2009; 15:639–658.
Mauser-Bunschoten EP, Kleine Budde I, Lopaciuk S, et al. An ultrapure plasma-derived monoclonal antibody-purified factor IX concentrate (Nonafact(R)), results of phase III and IV clinical studies. Haemophilia 2011; 17:439–445.
Strauss T, Lubetsky A, Ravid B, et al. Recombinant factor concentrates may increase inhibitor development: a single centre cohort study. Haemophilia 2011; 17:625–629.
Pruthi RK, Mathew P, Valentino LA, et al. Haemostatic efficacy and safety of bolus and continuous infusion of recombinant factor VIIa are comparable in haemophilia patients with inhibitors undergoing major surgery. Results from an open-label, randomized, multicenter trial. Thromb Haemost 2007; 98:726–732.
Iorio A, Matino D, D’Amico R, Makris M. Recombinant Factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with haemophilia and inhibitors. Cochrane Database Syst Rev 2010; (8):CD004449.
Hvas AM, Sorensen HT, Norengaard L, Christiansen K, Ingerslev J, Sorensen B. Tranexamic acid combined with recombinant factor VIII increases clot resistance to accelerated fibrinolysis in severe hemophilia A. J Thromb Haemost 2007; 5:2408–2414.
Coppola A, Windyga J, Tufano A, et al. Treatment for preventing bleeding in people with haemophilia or other congenital bleeding disorders undergoing surgery. Cochrane Database Syst Rev 2015; (2):CD009961.
Santagostino E, Escobar M, Ozelo M, et al. Recombinant activated factor VII in the treatment of bleeds and for the prevention of surgery-related bleeding in congenital haemophilia with inhibitors. Blood Rev 2015; 29 (Suppl 1):S9–S18.
Tran HT, Sorensen B, Rea CJ, et al. Tranexamic acid as adjunct therapy to bypassing agents in haemophilia A patients with inhibitors. Haemophilia 2014; 20:369–375.
Howman R, Barnes C, Curtin J, et al. The clinical efficacy and safety of the FVIII/VWF concentrate, BIOSTATE(R), in children with von Willebrand disorder: a multi-centre retrospective review. Haemophilia 2011; 17:463–469.
Federici AB, Barillari G, Zanon E, et al. Efficacy and safety of highly purified, doubly virus-inactivated VWF/FVIII concentrates in inherited von Willebrand’s disease: results of an Italian cohort study on 120 patients characterized by bleeding severity score. Haemophilia 2010; 16:101–110.
Federici AB, Sacco R, Stabile F, Carpenedo M, Zingaro E, Mannucci PM. Optimising local therapy during oral surgery in patients with von Willebrand disease: effective results from a retrospective analysis of 63 cases. Haemophilia 2000; 6:71–77.
Neff AT, Sidonio RF Jr. Management of VWD. Hematology Am Soc Hematol Educ Program 2014; 2014:536–541.